Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Cyclandelate

    go.drugbank.com/drugs/DB04838
    ApprovedWithdrawn

    Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.

  2. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

  3. Drug

    Nitroarginine

    go.drugbank.com/drugs/DB04223
    Investigational

    Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6) … An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity.

    Synonyms: N(gamma)-nitro-L-arginine
  4. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting the secondary solvent-front mutation _G2032R_ is 400 … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  5. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    Sativex® is available in a 1:1 formulation of THC:CBD as an oro-mucosal pump spray used for treatment of neuropathic pain from Multiple Sclerosis (MS) and for intractable cancer pain. … In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded

  6. Drug

    Resorcinol

    go.drugbank.com/drugs/DB11085
    ApprovedInvestigational

    It is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses

    Synonyms: m-Hydroquinone, m-hydroxyphenolMixtures: DG Health Feminine Anti-itch, BUCO-BLEU KOLLUTUVAR, 15 ML
  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in

  8. Drug

    Bismuth subgallate

    go.drugbank.com/drugs/DB13909
    Approved

    Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter … Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight.

    Mixtures: KORTOS KREM, 30 G
  9. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

  10. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer.

    Synonyms: 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin